# Contraline Raises $92.5M Series B for Male Hormonal Contraceptive Gel NES/T

> financing · REPORTED · 2026-06-02

On June 2, 2026, Charlottesville-based Contraline raised $92.5 million in a Series B round co-led by BVF Partners and RA Capital Management, with participation from GV, Lumira Ventures, and Invus. Proceeds will advance NES/T, an investigational once-daily reversible hormonal male contraceptive gel, into Phase 3 development.

About Contraline: Contraline is a women's and reproductive health company developing NES/T, a once-daily topical hormonal male contraceptive gel designed to provide a reversible, non-surgical family planning option, expanding contraceptive choices beyond those historically targeted solely at women.

- Company: Contraline
- Sector: women's health
- Primary source: https://wewillcure.com/insights/news/funding-and-models/womens-health-venture-capital-funding-tracker-2026

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.